Offers of Price Reductions for HIV/AIDS Drugs

Recent Documents



March 27, 2001. Abbott announced a price cut for two drugs (Ritonavir and Kaletra)and its HIV test, Determine. The dollar amount of the price cut is not specified - the company offers to sell the drugs and test "at no profit."

Bristol-Myers Squibb

March 14, 2001. Bristol-Myers Squibb announces that "The patent for Zerit [d4T]... will be made available at no cost to treat AIDS in South Africa." It also offers full transparency in pricing for drugs in Africa, pledges to raise funding for its Secure the Future program to $115 million, and offers to sell ddI and Zerit "below cost" (however, at a price over twice as high as that charged by generics firms).



March 7, 2001. Merck offers to sell Crixivan for $600 per patient per year and Stocrin for $500 per patient per year. Merck originally claimed that, unlike the price reductions offered by multinational pharmaceutical firms last year (including Merck) through the Accelerating Access Initiative, this lower price is available immediately. However, that afternoon Merck made it clear that it would not offer the lower prices to all poor countries, and that the deal would need to be worked out on a country-by-country basis.

In October 2002, Merck annouced further cuts in the price for Stocrin from the (already reduced) price of $1.37 per patient per day to $0.95 per patient per day in the poorest, hardest-hit countries. The price for middle-development countries with less than 1% HIV prevalence will be $2.10 per patient per day, down from $2.52.


February 7, 2001. Cipla, an Indian generic drug manufacturer, offered to supply triple-combination therapy for HIV/AIDS for $350 per patient per year to Medicins San Frontieres. It also offered to sell the therapy for $600 per patient per year to poor governments, on the condition that the recipient governments provide the drugs for free to those with HIV/AIDS. The cocktail consists of two 40 milligram tablets of stavudine, two 150 milligram tablets of lamivudine and two 200 milligram tablets of nevirapine. The cost of this regimen in developed nations is $10,000- $15,000 annually.

Accelerating Access Initiative

On May 11, 2000, GlaxoWellcome, Bristol Myers Squibb, Merck, Boehringer-Ingelheim, and Roche entered into this initiative along with UNAIDS, the World Health Organization, UNICEF, the World Bank, and the UN Development Program. The goal is to improve access to HIV/AIDS drugs in developing countries. Drug discounts are negotiated on a country-by-country basis. By April 9, 2001, the program has succeeded in getting drugs discounted in six countries: Rwanda, Uganda, Senegal, Cote d'Ivoire, Cameroon and Mali.


News Stories

Corrections or suggestions to Mike Palmedo

CPT Home CPT Health Care and Intellectual Property Page CPT Country Dispute page